Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2025 16:01 ET | Source: Femasys Inc.

Femasys Announces Third Quarter Financial Results for 2025

– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA,...
November 10, 2025 09:00 ET | Source: Femasys Inc.

Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets -- ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) --...
November 03, 2025 08:30 ET | Source: Femasys Inc.

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

-- Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured...
October 22, 2025 09:00 ET | Source: Femasys Inc.

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe

--Marks key milestone in European commercialization strategy under EU Medical Device Regulation (MDR)-- ATLANTA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical...
September 25, 2025 09:00 ET | Source: Femasys Inc.

Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership

ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective...
September 02, 2025 09:00 ET | Source: Femasys Inc.

Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

--Existing investors, including Femasys’ largest shareholders, reaffirm confidence in Femasys’ strategy for growth and impact in women’s health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys...
August 20, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

--Advances European commercialization strategy following CE mark approval-- ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making...
August 06, 2025 09:00 ET | Source: Femasys Inc.

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

--Initiation of access to FemBloc, a revolutionary non-surgical permanent contraceptive, as global availability accelerates-- ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY),...
July 22, 2025 08:50 ET | Source: Bonafide® Health, LLC

5th Annual State of Menopause Study, Long-Running Survey of Menopausal Women in US, Reveals Perimenopause May be Most Misunderstood Health Transition

New York, NY, July 22, 2025 (GLOBE NEWSWIRE) -- Bonafide Health, LLC, a women’s healthcare company that provides hormone-free, clinically researched solutions to effectively relieve perimenopause...
July 01, 2025 09:00 ET | Source: Femasys Inc.

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading...